KKR led a $22m Series B round in TearClear.

KKR led a $22m Series B round in TearClear, an emerging ophthalmic pharmaceutical company. Participating in the raise was Visionary Ventures, Bluestem Capital and Flying L Partners, who collaborated with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology. "Stuart is a life science industry executive with proven success in pharmaceuticals, biologics, medical devices and over‐the‐counter products. His appointment further strengthens our Board and his commercial expertise will be a tremendous value to the team," Robert Dempsey, TearClear CEO.